HotStockMarket › Forums › HSM Stock Forum › Penny Stocks › NVIV - InVivo Therapeutics
New Posts  All Forums:Forum Nav:

NVIV - InVivo Therapeutics - Page 2

post #21 of 295
11/25/11 at 11:30am

Thinking of selling some today ....

Reply
Reply
post #22 of 295
11/29/11 at 2:48pm
Thread Starter 

It is never a bad idea to take some profits especially after such a spectacular jump in the share price.

 

I sold a small portion of my position and looking for a better entry between $2.00 and $1.50.  That being said my core long term position is intact and I feel strongly that by Q4 2012 or Q1 2013 this stock will be trading between $7 and $10.  I also prefer to pay long term capital gains tax (15%) and therefore I want to hold my core position for >1 year.

 

There are $13M warrants that are exercisable at $1.40 and which will be called if the stock trades above $2.80 for 20 trading days.  This should raise ~$18M which should be enough to finish the clinical trial and get FDA approval for their first device. 

If they execute appropriately much dilution won't be necessary.

 

As far as the stock price is concerned there needs to be a consolidation between $2.80 and $2.00 for several weeks to form a higher base and support more upside. The churn will weed out the weak hands and allow for a run to $4 on some good news.

 

big.chart?nosettings=1&symb=nviv&uf=0&type=4&size=2&sid=5633708&style=320&freq=1&time=8&rand=2020669874&compidx=aaaaa%3a0&ma=0&maval=9&lf=1&lf2=0&lf3=0&height=335&width=579&mocktick=1
 

Quote:
Originally Posted by weitzwb24 View Post

I got in with 6500 shares at $0.86.  I am still debating selling enough to cover my initial investment and keep my "free" shares.  The big debate though is if I want to lower my ownership when some dilution will likely occur soon.

 

Decisions, decisions...



 

Reply
Reply
post #23 of 295
12/1/11 at 9:38am
Thread Starter 

For anyone interested in InVivo check out this most recent presentation by the CEO:

 

http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=NVIV.OB&item_id=4229203#

Reply
Reply
post #24 of 295
12/5/11 at 12:27pm
Thread Starter 

Loading up on some shares between $1.95 and $1.50 on this weakness.  

 

Be greedy when other's are fearful and fearful when others are greedy. :-)

 

big.chart?nosettings=1&symb=nviv&uf=0&type=4&size=2&sid=5633708&style=320&freq=1&time=7&rand=686764854&compidx=aaaaa%3a0&ma=0&maval=9&lf=1&lf2=0&lf3=0&height=335&width=579&mocktick=1

Reply
Reply
post #25 of 295
12/6/11 at 12:21pm
Thread Starter 

Technicals are starting to look good for a bottom at $1.78, but watch out because if that doesn't hold next support at $1.45 and $1.10.

 

nviv.png

Reply
Reply
post #26 of 295
12/7/11 at 2:57pm
Thread Starter 

Nice little bounce today.  I expect further consolidation until years end and then a run past $3 in Q1 2012 on FDA go ahead for first in man clinical study. 

Reply
Reply
post #27 of 295
12/7/11 at 2:59pm
Quote:
Originally Posted by amohedas View Post

Technicals are starting to look good for a bottom at $1.78, but watch out because if that doesn't hold next support at $1.45 and $1.10.

 

nviv.png


Hmm, yes charts!

 

I shall award you karma!

 

Reply
Reply
post #28 of 295
12/13/11 at 9:57am

I'm looking to start a position in this one, however I wonder if it won't come down some more on this light volume...

Reply
Reply
post #29 of 295
12/19/11 at 2:55pm
Thread Starter 

Low volume combined with the fact that there is overall market weakness = lower prices.

 

How low?  I'm not sure, but if you are interested in starting a position in this stock I would advise placing a few bids at various levels of support like at $1.90 and $1.75 etc.

 

The stock is consolidating very nicely at this level which is bullish in my opinion.  2012 should be a great year for InVivo but investors must have patience with biotech stocks.

 

big.chart?nosettings=1&symb=nviv&uf=0&type=4&size=2&sid=5633708&style=320&freq=1&time=7&rand=933263654&compidx=aaaaa%3a0&ma=0&maval=9&lf=1&lf2=0&lf3=0&height=335&width=579&mocktick=1
 

Quote:
Originally Posted by Fizz1030 View Post

I'm looking to start a position in this one, however I wonder if it won't come down some more on this light volume...



 

Reply
Reply
post #30 of 295
12/20/11 at 9:35am

Is there news that leaked this morning?  A bit of a pop this morning on high volume... 2.30x2.35

Reply
Reply
post #31 of 295
12/20/11 at 12:25pm

Someone just bought 40k at $2.40...

Reply
Reply
post #32 of 295
12/20/11 at 4:16pm
Thread Starter 

Apparently a newsletter (BI Research) recommended NVIV today and that is the reason for the increased volume.

 

No news. Chart is looking good.

Quote:
Originally Posted by Fizz1030 View Post

Is there news that leaked this morning?  A bit of a pop this morning on high volume... 2.30x2.35



 

Reply
Reply
post #33 of 295
12/22/11 at 12:25pm
Thread Starter 

Very nice consolidation at ~$2 with a bottom on Dec 6 @ $1.75.  Now volume and interest are back and we could be heading past $3 to $3.50 in short order.

 

Looking to breakout past the previous 52-week high:

 

big.chart?nosettings=1&symb=nviv&uf=0&type=4&size=2&sid=5633708&style=320&freq=1&time=7&rand=344181982&compidx=aaaaa%3a0&ma=0&maval=9&lf=1&lf2=0&lf3=0&height=335&width=579&mocktick=1

Reply
Reply
post #34 of 295
12/22/11 at 1:27pm

Looks like the company just acquired another 2mil in working capital yesterday... looking good.

 

http://biz.yahoo.com/e/111222/nviv.ob8-k.html


Edited by Fizz1030 - 12/22/11 at 2:47pm
Reply
Reply
post #35 of 295
12/22/11 at 4:29pm
Thread Starter 

Nice capital raise at a good price ($2.04) plus warrants with an excercise price at $3.06. This should put a solid floor on the stock between $2 and $3 as we build a higher base.

 

Also if NVIV trades above $2.80 for 20 consecutive trading days they can call on 12.85M warrants at $1.40 per share and raise another $18M. 

 

This should be enough to pay for general administrative expenses as well as the necessary trials for approval of the first product.  Hopefully from their continuing operations can be paid from cashflow.

 

Quote:
Originally Posted by Fizz1030 View Post

Looks like the company just acquired another 2mil in working capital yesterday... looking good.

 

http://biz.yahoo.com/e/111222/nviv.ob8-k.html



 

 

Reply
Reply
post #36 of 295
12/22/11 at 4:53pm
Thread Starter 

InVivo has the BI report posted on their website. I'll post the link below and an excerpt (emphasis mine). It's as if the publisher of the report read this thread (check my first few posts, it was ALL there!). 

 

http://invivotherapeutics.com/pdf/BI%20Resesearch%20Report%20Dated%20December%2021,%202011.pdf

 

 

Quote:
This is likely the most exciting company I 
have ever come across, led by an infectious and 
energetic CEO that was paralyzed himself.  What 
else?  Oh!  Talk about holy grails of medicine-  
InVivo has yet another technology whereby the 
scarred damaged portion of the spinal cord that is 
causing paralysis for those in wheel chairs for years
is cut out and replaced by their scaffold material 
seeded with neural stem cells, this is their “Miami 
project.” InVivo has sufficient cash (from a $13 
million stock offering) plus more that can be called 
in as needed from 18 million of warrants at $1.40. 
InVivo also has over 100 patents filed to protect
everything.  There is no BI Rank, but NVIV will be 
my Best Idea for 2012.  Volume is borderline so use 
limit orders <$2.75.  And check the website, the 
resumes there, and ALL the videos, especially the 
last video from TDEx Boston 9/2010.  It’s 17 
minutes and is to the right of “Play Video” on the 
home page.  And if all this doesn’t prompt you to 
get a few shares … check your pulse.  The heavy 
involvement of Dr. Langer here, who has headed
the FDA’s Science Board and whose patents are 
licensed by over 220 companies, lends added 
confidence to this investment, but of course, there 
are no guarantees.

 


Quote:
Originally Posted by amohedas View Post

Apparently a newsletter (BI Research) recommended NVIV today and that is the reason for the increased volume.

 

No news. Chart is looking good.



 



 

Reply
Reply
post #37 of 295
12/23/11 at 11:03am
Thread Starter 

BlueSky breakout.  This is a beautiful thing:

 

big.chart?nosettings=1&symb=nviv&uf=0&type=4&size=2&sid=5633708&style=320&freq=1&time=7&rand=2045228527&compidx=aaaaa%3a0&ma=0&maval=9&lf=1&lf2=0&lf3=0&height=335&width=579&mocktick=1

Reply
Reply
post #38 of 295
12/23/11 at 3:04pm
Thread Starter 

New article:

 

 

 

Quote:

When a CEO’s Personal Interest Inspires a Company’s Mission (OTC:NVIV)

 

What drew me to Invivo Therapeutics Holdings Corp (OTC:NVIV) wasn’t its scientific endeavors so much as the story of Frank Reynolds, its Chairman of the Board, CEO, and CFO…

Mr. Reynolds suffered a paralyzing injury to his spine in Dec 1992. While recovering from this injury he spent years gaining subject matter expertise on the spine and spinal cord. So the CEO is personally vested by experience in what he is developing through the Company he works for.

That may sound like he could be lacking objectivity as a leader; but trust me,this fellow has an academic business pedigree that is impressive and was too long to place here; needless to say that by the time you get down to Wharton Business School; you start to drift... 

Warren Buffet always invested in what was significantly personal; he bought Coke because he drank Coke and he bought See’s Candy because he ate See’s Candy and all writers know in their youth ‘write about what you know’and only is it the rare occasion, the auto industry for example, when leadership is sometimes best served by those who know nothing about cars.

NVIV is a development-stage company that is developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. The devices are meant to protect the damaged spinal cord from further secondary injury and promote neuroplasticity, a process where functional recovery can occur through the rerouting of signalling pathways to the spared healthy tissue.

The Company’s three product candidates in development are: 1) a biocompatible polymer scaffolding device to treat acute Spinal Cord Injury (SCI); 2) a biocompatible hydrogel for local controlled release of methylprednisolone to treat acute SCI; and 3) a biocompatible polymer scaffolding device seeded with chemicals to treat acute and chronic SCI.

The scaffoldings serves as a ladder of sorts for the controlled delivery of anti-inflammatory pharmaceuticals and regenerative cell therapies directly delivered to the injury site. This technology, based on several decades of research at MIT's Langer Lab, has shown effect in preclinical studies at treating the spinal cord and is being advanced into clinical development by NVIV in a clinical-stage pilot study in 2012.

The Company’s latest 10-Q reveals it has cash to fund operations through March 31 ’12 and the Q has all the typical marks of a development company; lots of expenses, operating costs, and the like, but I believe it can survive its development days because its technology is so desperately need and the FDA knows it. A little funding from the National Institute for Health wouldn’t hurt during the NVIV start-up days. 

I think the CEO has the passion to take everything forward; step by step… 

 

 

Reply
Reply
post #39 of 295
12/24/11 at 6:00pm

I wonder why they are only going to try their scaffold device in the first human trial instead of combining the structure with their hydrogel?  I don't know a lot of the medical details, but has InVivo said when they plan to test the gel on humans as well?  From the investor presentation, it looks like they had given the primates the full treatment, and I'm sure the gel was probably a big success factor in the primate trials...  Anyone have any insights?

Reply
Reply
post #40 of 295
12/25/11 at 11:40pm

Fizz, I think if I remember the timeline correctly, the data to support human clinical trials, on the hydrogel, was not out yet when they first submitted the scaffold for IDE with the FDA.

Reply
Reply
New Posts  All Forums:Forum Nav:
  Return Home
  Back to Forum: Penny Stocks
HotStockMarket › Forums › HSM Stock Forum › Penny Stocks › NVIV - InVivo Therapeutics